ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

8,737Medicare Part D Prescriptions Filled, Including Refills
$814K Total Retail Price of All Prescriptions
587 Patients Receiving at Least One Drug in Part D
81%Patients 65 Years and Older
48% Subsidized Claims for Low-Income Patients

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume .

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category
ATORVASTATIN CALCIUM 344 293
SIMVASTATIN 311 257
AMLODIPINE BESYLATE 242 226
FUROSEMIDE 229 197
LEVOTHYROXINE SODIUM 185 134
OMEPRAZOLE 180 149
METHYLPREDNISOLONE 155 123
METFORMIN HCL 148 118
WARFARIN SODIUM 140 115
METOPROLOL SUCCINATE 137 122
ADVAIR DISKUS 129 86
SPIRIVA 120 109
CARVEDILOL 117 96
LIPITOR 113 105
PROAIR HFA 109 66
DIOVAN 105 89
CRESTOR 104 95
RAMIPRIL 103 91
METOPROLOL TARTRATE 98 80
NEXIUM 94 70
CLOTRIMAZOLE-BETAMETHASONE 93 59
ZOLPIDEM TARTRATE 93 71
PANTOPRAZOLE SODIUM 91 74
ALENDRONATE SODIUM 90 84
CLOPIDOGREL 87 84
HYDROCHLOROTHIAZIDE 86 67
SINGULAIR 81 64
PREDNISONE 80 71
FAMOTIDINE 77 70
TRAMADOL HCL 75 38
DOXYCYCLINE HYCLATE 75 58
PLAVIX 75 74
OXYCODONE-ACETAMINOPHEN 74 58 S2
HYDROCODONE-ACETAMINOPHEN 74 49 S3
LISINOPRIL 73 62
POTASSIUM CHLORIDE 69 58
BENICAR HCT 66 61
LEVOFLOXACIN 64 55
AMOX TR-POTASSIUM CLAVULANATE 62 47
JANUVIA 61 44
LANTUS SOLOSTAR 60 30
DIOVAN HCT 55 55
CELEBREX 55 47
IBANDRONATE SODIUM 54 41
FLUTICASONE PROPIONATE 52 32
SERTRALINE HCL 52 30
TRICOR 52 39
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on July 8, 2007.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.